Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460034 | 0.88 | KDM4E (0.37) | MRGPRX4PTGER1 | |
| SCHEMBL2458336 | 0.88 | KDM4C (0.32) | MRGPRX4PTGER1KDM4CMAP4K4 | |
| SCHEMBL2461788 | 0.86 | PDE4A (0.32) | — | |
| SCHEMBL2458350 | 0.84 | MRGPRX4 (0.38) | MRGPRX4 | |
| SCHEMBL2457091 | 0.83 | MRGPRX4 (0.33) | MRGPRX4PTGER1 | |
| SCHEMBL2459494 | 0.79 | KDR (0.35) | MAP4K4 | |
| SCHEMBL2462727 | 0.77 | KMO (0.30) | — | |
| SCHEMBL2460708 | 0.76 | KDM4E (0.35) | MRGPRX4 | |
| SCHEMBL2460343 | 0.74 | PDE4A (0.32) | — | |
| SCHEMBL396470 | 0.73 | AR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | MRGPRX4 1767/4885PTGER1 3389/4885KDM4C 2195/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | MRGPRX4 1767/4885PTGER1 3389/4885KDM4C 2195/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | MRGPRX4 1767/4885PTGER1 3389/4885KDM4C 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.